Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab

Modern Rheumatology

Volumn 22, Issue 6, 2012, Pages 871-876

  Shinoki, Toshihiko ^a,b   Hara, Ryoki ^b   Kaneko, Utako ^b   Miyamae, Takako ^b   Imagawa, Tomoyuki ^b   Mori, Masaaki ^b   Yokota, Shumpei ^b  

^a SUZUKA GENERAL HOSPITAL   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Influenza vaccine; Systemic onset juvenile idiopathic arthritis; Tocilizumab

Indexed keywords

INFLUENZA VACCINE; PREDNISOLONE; TOCILIZUMAB;

ADOLESCENT; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; ERYTHEMA; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; INFLUENZA; JUVENILE RHEUMATOID ARTHRITIS; MALE; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SKIN INDURATION; SKIN SWELLING; TREATMENT DURATION; TREATMENT RESPONSE; VACCINATION;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE;

EID: 84870324299     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-012-0595-z     Document Type: Article

References (19)

1. Kanakoudi-Tsakalidou F, Trachana M, Pratsidou-Gertsi P, Tsitsami E, Kyriazopoulou-Dalaina V. Influenza vaccination in children with chronic rheumatic diseases and long-Term immunosuppressive therapy. Clin Exp Rheumatol. 2001;19(5):589-94.
2. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371(9617):998-1006.
3. Hirano T, Yasukawa K, Harada H, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature. 1986;324(6092):73-6.
4. Yoshizaki K, Nakagawa T, Fukunaga K, Tseng LT, Yamamura Y, Kishimoto T. Isolation and characterization of B cell differentiation factor (BCDF) secreted from a human B lymphoblastoid cell line. J Immunol. 1984;132(6):2948-54.
5. International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390-2.
6. Belshe RB, Newman FK, Cannon J, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med. 2004;351(22):2286-94.
7. Gelinck LB, van der Bijl AE, Beyer WE, et al. The effect of antitumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis. 2008;67(5):713-6.
8. Kawai N, Ikematsu H, Iwaki N, et al. Analysis of the incidence of influenza, the response of influenza vaccination and the effectiveness of anti-influenza drugs in the 2007-2008 winter season in Japan (in Japanese). Japan Med J 2008;4416:70-5.
9. Aikawa NE, Campos LM, Silva CA, et al. Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. J Rheumatol 2011;39:167-73. doi:10.3899/jrheum.110721.
10. Wallin L, Quintilio W, Locatelli F, et al. Safety and efficiency of influenza vaccination in systemic lupus erythematosus patients. Acta Reumatol Port. 2009;34:498-502.
11. Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol. 2007;34(2):272-9.
12. Kapetanovic MC, Saxne T, Nilsson JA, Geborek P. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford). 2007;46(4):608-11.
13. Kubota T, Nii T, Nanki T, Kohsaka H, et al. Anti-Tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2007;17(6):531-3.
14. Fomin I, Caspi D, Levy V, et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis. 2006;65(2): 191-4.
15. Salemi S, Picchianti-Diamanti A, Germano V, et al. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity. Clin Immunol. 2010;134(2):113-20.
16. Elkayam O, Bashkin A, Mandelboim M, et al. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum. 2010;39(6): 442-7.
17. Shale M, Czub M, Kaplan GG, Panaccione R, Ghosh S. Antitumor necrosis factor therapy and influenza: keeping it in perspective. Therap Adv Gastroenterol. 2010;3(3):173-7.
18. Muhammad K, Roll P, Seibold T, et al. Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and modulation of mutational targeting in memory B cells. Ann Rheum Dis. 2011;70:1507-10.
19. Roll P, Muhammad K, Schumann M, et al. In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment. Arthritis Rheum. 2011;63:1255-64.